Zentalis Pharmaceuticals Inc (ZNTL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.99-2.92%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ZNTL
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete enrollment in all cohorts of DENALI Part 2 and provide a topline readout to support potential accelerated approval in Cyclin E1-positive PROC patients.
Stated as a priority in 3 of last 3 quarters. Management expects to complete enrollment in all DENALI Part 2 cohorts and provide a topline readout by year-end 2026 or 1H 2027. Cash decreased from $211.8M in 2026-Q1 to $174.6M in 2026-Q2, with operating expenses rising from $37.9M to $44.4M, reflecting ongoing trial costs. The trajectory shows continued focus and progress toward enrollment completion and data readout.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Zentalis expects to complete enrollment in all cohorts of DENALI Part 2 and provide a topline readout by 1H 2027.”
“Zentalis expects to complete enrollment in all cohorts of DENALI Part 2 and provide a topline readout by year-end 2026.”
“DENALI Part 2 topline readout expected by year end 2026.”
Initiate and enroll patients in the ASPENOVA Phase 3 confirmatory trial to support full approval of azenosertib in Cyclin E1-positive PROC.
Stated as a priority in 3 of last 3 quarters. The first patient was dosed in the ASPENOVA Phase 3 trial in 2026-Q1, with enrollment ongoing to support full approval. The trial is designed to enroll about 420 patients. Management continues to emphasize this confirmatory trial as a key step toward regulatory approval, showing active advancement.
“We continue to advance the confirmatory ASPENOVA Phase 3 trial with the goal of bringing a potential first-in-class WEE1 therapy to market.”
“ASPENOVA Phase 3 confirmatory trial in Cyclin E1-positive PROC initiated with first patient dosed.”
“DENALI Part 2 topline readout expected by year end 2026; ASPENOVA Phase 3 trial initiation expected Q2 2026.”
Select optimal monotherapy dose of azenosertib and advance combination therapy trials including MUIR Phase 1b and expansion cohorts.
Stated as a priority in 3 of last 3 quarters. Management selected 400mg QD 5:2 as the optimal monotherapy dose in 2026-Q1 and continues to enroll combination therapy trials including MUIR. MUIR Part 1 data presented at ASCO 2026 showed 39% ORR and 7.3 months median PFS, supporting ongoing development. The trajectory shows active dose optimization and combination trial expansion.
“Enrollment completed in Part 2a and 2b of DENALI; Part 2c is enrolling; MUIR Part 2 enrollment ongoing.”
“400mg QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk profile in DENALI Part 2a.”
“Data from Part 1 of the Phase 1b MUIR trial to be presented at ASCO 2026 showing encouraging clinical activity.”
Present clinical and preclinical data at major oncology conferences to support clinical development and regulatory strategy.
Stated as a priority in 2 of last 3 quarters. Management presented MUIR Part 1 data at ASCO 2026 and had abstracts accepted at ESMO 2026 and AACR 2026, supporting pipeline visibility. These presentations align with the clinical development timeline and regulatory strategy, showing consistent communication of data.
“MUIR clinical trial data presented at ASCO 2026; ESMO 2026 abstracts accepted for DENALI and ASPENOVA.”
“AACR 2026 posters presented preclinical data and real-world data supporting azenosertib development.”
Manage cash and expenses to ensure sufficient capital to fund operations and clinical development through late 2027.
Stated as a priority in 3 of last 3 quarters. Cash and equivalents declined from $245.9M in 2025-Q4 to $174.6M in 2026-Q2, reflecting ongoing operating losses and investment in clinical programs. Management affirms runway into late 2027 to support key milestones, indicating financial discipline to sustain operations.
“Cash, cash equivalents and marketable securities were $174.6 million as of June 30, 2026, providing runway into late 2027.”
“Cash position of $211.8 million as of March 31, 2026, providing runway into late 2027.”
“Cash, cash equivalents and marketable securities were $245.9 million as of December 31, 2025.”
Over the trailing year it converted 1.18x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
13 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.